Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
Nikitin E, Kislova M, Morozov D, Belyakova V, Suvorova A, Sveshnikova J, Vyscub G, Matveeva I, Shirokova M, Shipaeva A, Klitochenko T, Makarovskaya P, Dmitrieva E, Biderman B, Sudarikov A, Obukhova T, Samoilova O, Kaplanov K, Konstantinova T, Mayorova O, Poddubnaya I, Ptushkin V. Nikitin E, et al. Among authors: dmitrieva e. Leukemia. 2023 Jul;37(7):1464-1473. doi: 10.1038/s41375-023-01891-3. Epub 2023 May 18. Leukemia. 2023. PMID: 37202442 Free PMC article.
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
Kochneva ОL, Kislova M, Zhelnova EI, Petrenko AA, Baryakh EA, Yatskov KV, Dmitrieva EA, Misurina EN, Nikitin KE, Vasilieva EJ, Samsonova IV, Ptushkin VV, Baranova A, Nikitin EA. Kochneva ОL, et al. Among authors: dmitrieva ea. Leuk Lymphoma. 2022 Jul;63(7):1607-1616. doi: 10.1080/10428194.2022.2034157. Epub 2022 Feb 13. Leuk Lymphoma. 2022. PMID: 35156528
Significant reduction in the incidence of non-coronavirus infections in patients with chronic lymphocytic leukemia on ibrutinib and venetoclax treatment during the COVID-19 pandemic: An additional benefit of lockdown.
Kislova M, Petrenko A, Dmitrieva EA, Milenkin A, Nikitin KE, Ptushkin VV, Shabunin AV, Nikitin EA. Kislova M, et al. Among authors: dmitrieva ea. Hematol Oncol. 2023 Oct;41(4):683-693. doi: 10.1002/hon.3156. Epub 2023 Apr 14. Hematol Oncol. 2023. PMID: 37058711
Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia.
Komissarov AA, Kislova M, Molodtsov IA, Petrenko AA, Dmitrieva E, Okuneva M, Peshkova IO, Shakirova NT, Potashnikova DM, Tvorogova AV, Ptushkin VV, Efimov GA, Nikitin EA, Vasilieva E. Komissarov AA, et al. Among authors: dmitrieva e. Int J Mol Sci. 2022 Dec 27;24(1):416. doi: 10.3390/ijms24010416. Int J Mol Sci. 2022. PMID: 36613860 Free PMC article.
Russian Science and Technology: Rise or Progressive Lag (Part I).
Klepach AN, Vodovatov LB, Dmitrieva EA. Klepach AN, et al. Among authors: dmitrieva ea. Stud Russ Econ Dev. 2022;33(6):631-644. doi: 10.1134/S1075700722060077. Epub 2022 Nov 28. Stud Russ Econ Dev. 2022. PMID: 36466731 Free PMC article.
194 results